Breaking News Instant updates and real-time market news.

PBYI

Puma Biotechnology

$38.05

1.35 (3.68%)

16:47
03/01/17
03/01
16:47
03/01/17
16:47

Puma Biotechnology to modify summary of product characteristics in MAA

Puma Biotechnology announced that based on its recent meeting with the Rapporteur, Co-Rapporteur and review team members, as well as the European Medicines Agency, the company plans to modify the summary of product characteristics, sometimes referred to as the European product label, in its Marketing Authorisation Application to restrict the intended population to patients initiating neratinib treatment within one year after completion of adjuvant trastuzumab therapy. The proposed SmPC will continue to include both hormone receptor positive and hormone receptor negative patients. Puma recently conducted a meeting with the Rapporteur, Co-rapporteur and members of the review team as well as EMA to discuss the responses to the 120-day list of questions received in connection with the Company's MAA for neratinib that was submitted in the summer of 2016. The initially proposed indication was for the "extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant trastuzumab based therapy." During this meeting it was discussed that neratinib would likely be sequenced immediately after adjuvant trastuzumab and more benefit was observed in the subgroup of patients who received neratinib within 1 year from prior trastuzumab completion when compared with those patients receiving neratinib after 1 year from the completion of prior trastuzumab treatment. In addition, data from the pivotal adjuvant trastuzumab trials suggest that patients are at higher risk of recurrence closer to completion of adjuvant trastuzumab, and the risk of recurrence may decrease over time. Based on this meeting, Puma will be revising the proposed SmPC in its MAA for neratinib to restrict the intended population to those patients initiating neratinib treatment within one year after completion of adjuvant trastuzumab therapy. The Committee for Medicinal Products for Human Use is continuing to review Puma's MAA and has not yet made a final decision to recommend approval of the drug for the updated or any other indication and there is no guarantee when, if ever, the MAA will be approved. The tables below, based on the interim 5 year analysis announced in July 2016, show results for the invasive disease free survival of the initially proposed intent to treat population and the intent to treat population in the subgroup of patients who initiated neratinib treatment within one year after completion of adjuvant trastuzumab therapy.

  • 21

    Jul

PBYI Puma Biotechnology
$38.05

1.35 (3.68%)

11/14/16
JPMS
11/14/16
NO CHANGE
JPMS
Puma Biotechnology selloff today an overreaction, says JPMorgan
JPMorgan analyst Cory Kasimov views the selloff today in shares of Puma Biotechnology as an overreaction. The diarrhea rates included in abstract posted today are worse than the last update, but the rates are equivalent to a median number of around 1 episode per patient in the first cycle of treatment, Kasimov tells investors in an intraday research note. He continues to consider neratinib an approvable drug based on currently available data.
11/14/16
STFL
11/14/16
NO CHANGE
Target $88
STFL
Buy
Stifel calls Puma selloff overdone, but concerned by management comments
Stifel analyst Thomas Shrader views the intraday selloff in Puma Biotechnology shares as an overreaction, but he calls management's comments last week "an issue." At a conference last week, management said, "In December, we showed the interim results of this and as you can see the grade 3 diarrhea ranged from 13% to 18%. And also, all of the things that would be involved in tolerability, like stopping the drug, reducing the drug, or discontinuing were all brought down as well. Here, you can see the diarrhea over time in the control study." Shrader believes today's abstract was likely embargoed, but he still finds last week's comments "strange." Nonetheless, the analyst feels neratinib's Grade 3 diarrhea rate is manageable and he notes that Grade 4 diarrhea events were zero in all arms of the trial. Shrader has a Buy rating on Puma with an $88 price target.
01/03/17
SBSH
01/03/17
NO CHANGE
Target $88
SBSH
Buy
Citi finds 'bullish' Youtube videos for Puma cancer drug
Two new "Key Opinion Leader" videos expressing continued optimism on Puma Biotechnology's breast cancer drug neratinib posted on Youtube within the last several weeks, Citi analyst Yigal Nochomovitz tells investors in a research note. Similar to two videos posted in August, the new videos have received very little online attention with 25-30 views, the analyst contends. Nochomovitz believes Key Opinion Leader interest in neratinib continues to accelerate. The analyst notes a doctor in one of the videos said the chances of getting "significant diarrhea go way, way down" after a month. He keeps a Buy rating on Puma shares with an $88 price target. The stock closed Friday up 15c to $30.70.
02/01/17
SBSH
02/01/17
NO CHANGE
Target $88
SBSH
Buy
Citi sees Puma doubling if Roche study is negative
Citi analyst Yigal Nochomovitz believes shares of Puma Biotechnology (PBYI) could rally 100% or more if Roche (RHHBY) reports a negative Phase III Aphinity study readout of Perjeta in the adjuvant treatment of HER2-positive early breast cancer. The analyst, which notes Roche slides today point to a data readout in late February or early March, sees maximum downside for Puma shares of 30% should Aphinity succeed. A selloff would be a "very good opportunity to buy the dip" as despite the controversy around neratinib's benefit/risk profile, neratinib should be approved by the FDA for extended adjuvant, Nochomovitz tells investors in a research note. The FDA action date for neratinib is in July. The analyst adds that recent stock sales by Puma management were in the context of tax obligations required for vesting of restricted stock units. Management's net ownership in the company has actually increased with the vesting of a tranche of restricted stock, Nochomovitz writes. He has a Buy rating on Puma with an $88 price target. The stock is unchanged at $32.40 in morning trading.

TODAY'S FREE FLY STORIES

LOW

Lowe's

$81.46

1.24 (1.55%)

09:05
11/21/17
11/21
09:05
11/21/17
09:05
Hot Stocks
Lowe's says U.S. had positive comps in all categories in Q3 »

Comments from Q3 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CIDM

Cinedigm

$1.43

0.12 (9.16%)

09:05
11/21/17
11/21
09:05
11/21/17
09:05
Hot Stocks
Cinedigm receives CFIUS approval for Bison Capital strategic investment »

Cinedigm announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:05
11/21/17
11/21
09:05
11/21/17
09:05
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

CAVM

Cavium

$84.02

8.19 (10.80%)

, MRVL

Marvell

$21.59

1.3 (6.41%)

09:04
11/21/17
11/21
09:04
11/21/17
09:04
Downgrade
Cavium, Marvell rating change  »

Cavium downgraded to…

CAVM

Cavium

$84.02

8.19 (10.80%)

MRVL

Marvell

$21.59

1.3 (6.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

INWK

InnerWorkings

$10.47

0.01 (0.10%)

09:04
11/21/17
11/21
09:04
11/21/17
09:04
Hot Stocks
InnerWorkings selected by Trinchero Family Estates as marketing partner »

InnerWorkings announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYHT

Shineco

$3.53

-0.22 (-5.87%)

09:03
11/21/17
11/21
09:03
11/21/17
09:03
Hot Stocks
Shineco subsidiary enters into RMB1.12B agreement for industrial park in China »

Shineco announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$189.22

4.83 (2.62%)

09:02
11/21/17
11/21
09:02
11/21/17
09:02
Hot Stocks
L3 Technologies announces Free Space Optics contract awards »

L3 Technologies announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

YRD

Yirendai

$45.10

3.55 (8.54%)

, XRF

China Rapid Finance

$9.13

0.07 (0.77%)

09:02
11/21/17
11/21
09:02
11/21/17
09:02
Hot Stocks
Qudian, Yirendai slide after report of China suspension on new micro lenders »

Shares of China's…

YRD

Yirendai

$45.10

3.55 (8.54%)

XRF

China Rapid Finance

$9.13

0.07 (0.77%)

QD

Qudian

$20.08

-1.12 (-5.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZAYO

Zayo Group

$36.41

1.07 (3.03%)

09:02
11/21/17
11/21
09:02
11/21/17
09:02
Syndicate
Zayo Group 4.7M share Block Trade priced at $36.00 »

Barclays acted as sole…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

09:02
11/21/17
11/21
09:02
11/21/17
09:02
Recommendations
AT&T, Time Warner analyst commentary  »

AT&T price target…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

SGY

Stone Energy

$35.49

1.15 (3.35%)

09:02
11/21/17
11/21
09:02
11/21/17
09:02
Conference/Events
Stone Energy to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$98.95

-6.52 (-6.18%)

09:01
11/21/17
11/21
09:01
11/21/17
09:01
Recommendations
Incyte analyst commentary  »

Incyte price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

TMUS

T-Mobile

$60.30

0.28 (0.47%)

09:00
11/21/17
11/21
09:00
11/21/17
09:00
Upgrade
T-Mobile rating change  »

T-Mobile upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRL

Hormel Foods

$33.40

0.28 (0.85%)

08:59
11/21/17
11/21
08:59
11/21/17
08:59
Technical Analysis
Technical View: Hormel Foods trades up after earnings beat »

Shares were last up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

SNSS

Sunesis

$2.87

0.01 (0.35%)

, ABBV

AbbVie

$93.60

-0.01 (-0.01%)

08:58
11/21/17
11/21
08:58
11/21/17
08:58
Initiation
Sunesis, AbbVie initiated  »

Oppenheimer says Sunesis…

SNSS

Sunesis

$2.87

0.01 (0.35%)

ABBV

AbbVie

$93.60

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSW

DSW

$22.53

0.38 (1.72%)

08:57
11/21/17
11/21
08:57
11/21/17
08:57
Technical Analysis
Technical View: DSW down sharply after earnings, outlook, miss consensus »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

A

Agilent

$69.96

1.17 (1.70%)

08:57
11/21/17
11/21
08:57
11/21/17
08:57
Recommendations
Agilent analyst commentary  »

Agilent price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

GE

General Electric

$17.98

-0.23 (-1.26%)

, BAC

Bank of America

$26.74

0.12 (0.45%)

08:55
11/21/17
11/21
08:55
11/21/17
08:55
Options
Notable open interest changes for November 21st »

Monday's total…

GE

General Electric

$17.98

-0.23 (-1.26%)

BAC

Bank of America

$26.74

0.12 (0.45%)

BABA

Alibaba

$188.00

2.87 (1.55%)

AAPL

Apple

$169.98

-0.17 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGY

Stone Energy

$35.49

1.15 (3.35%)

08:55
11/21/17
11/21
08:55
11/21/17
08:55
Hot Stocks
Breaking Hot Stocks news story on Stone Energy »

Stone Energy trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NETS

Netshoes

08:53
11/21/17
11/21
08:53
11/21/17
08:53
Recommendations
Netshoes analyst commentary  »

Netshoes valuation overly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUB

Cubic

$53.50

0.5 (0.94%)

08:51
11/21/17
11/21
08:51
11/21/17
08:51
Recommendations
Cubic analyst commentary  »

Cubic price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

AXGN

AxoGen

$24.30

0.7 (2.97%)

08:51
11/21/17
11/21
08:51
11/21/17
08:51
Recommendations
AxoGen analyst commentary  »

AxoGen price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

CPB

Campbell Soup

$49.93

0.21 (0.42%)

08:48
11/21/17
11/21
08:48
11/21/17
08:48
Hot Stocks
Campbell continues to expect Campbell Fresh to return to profitability this year »

Says back to normal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

GE

General Electric

$17.98

-0.23 (-1.26%)

08:48
11/21/17
11/21
08:48
11/21/17
08:48
Recommendations
General Electric analyst commentary  »

Deutsche Bank cuts target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EV

Eaton Vance

$52.27

0.48 (0.93%)

08:48
11/21/17
11/21
08:48
11/21/17
08:48
Hot Stocks
Eaton Vance reports AUM $382.4B for FY17 »

This represents an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.